SOT recipient demographics and disease characteristics
| Age, y . | Sex . | SOT . | Age at transplant . | Graft rejection prophylaxis . | Clinical concern . | BKPyV treatment before VSTs . | Pre-VST viremia, copies/mL . | No. TP-VST given . | Therapy outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 16 | Male | Heart | 11 y | Everolimus | EBV/PTLD CKD BK viremia | Leflunomide Cidofovir IVIG IST reduction (CHOP for PTLD) | BKPyV: 12 000 000 EVB: 132 000 | 3 | BKPyV: PR EBV: cleared EBV viremia and resolved PTLD on PET scan |
| 10 | Male | Heart and kidney | Heart: 1 mo Kidney: 4 y | Tacrolimus + prednisone | EBV and BK viremia and history of nephropathy in first kidney transplant | Cidofovir Leflunomide IVIG IST reduction | BK: 1 000 EBV: 15 000 | 10 | BK: cleared EBV: cleared. Received second kidney transplant, no graft rejection |
| 10 | Female | Kidney | 9 y | Tacrolimus | Persistent BK viremia | Cidofovir, leflunomide IVIG IST reduction | BK: 9 700 | 1 | BK viremia reduced 2000 copies/mL, no graft rejection |
| Age, y . | Sex . | SOT . | Age at transplant . | Graft rejection prophylaxis . | Clinical concern . | BKPyV treatment before VSTs . | Pre-VST viremia, copies/mL . | No. TP-VST given . | Therapy outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 16 | Male | Heart | 11 y | Everolimus | EBV/PTLD CKD BK viremia | Leflunomide Cidofovir IVIG IST reduction (CHOP for PTLD) | BKPyV: 12 000 000 EVB: 132 000 | 3 | BKPyV: PR EBV: cleared EBV viremia and resolved PTLD on PET scan |
| 10 | Male | Heart and kidney | Heart: 1 mo Kidney: 4 y | Tacrolimus + prednisone | EBV and BK viremia and history of nephropathy in first kidney transplant | Cidofovir Leflunomide IVIG IST reduction | BK: 1 000 EBV: 15 000 | 10 | BK: cleared EBV: cleared. Received second kidney transplant, no graft rejection |
| 10 | Female | Kidney | 9 y | Tacrolimus | Persistent BK viremia | Cidofovir, leflunomide IVIG IST reduction | BK: 9 700 | 1 | BK viremia reduced 2000 copies/mL, no graft rejection |
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; IST, immunosuppressive therapy; PET, positron emission tomography; TP-VSTs, third-party donor VSTs.